semaglutide tablets patent expiry Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. 💉 Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Ozempic's Key Molecule To Go

Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity [Internet]

Fatigue and reduced energy are occasionally reported, particularly during the first few weeks of treatment

Fernandes SA, Demetriades C

Additionally, they had a 20% lower risk of having a stroke or heart attack

But opting for cold food may be easier to digest

It is distinct from Rybelsus, which is lower-dose oral semaglutide for type 2 diabetes, and, following MHRA approval in June 2026, is rolling out on private prescription during the second half of 2026 rather than on the NHS